Paper presentation on Impect assessment of rota virus vaccine on acute gastroenteritis and it's safety with focus on intussuception for pedia resident
rotavirus vaccine efficacy acute gastroenteritis RCT Rotarix RotaTeq
rotavirus vaccine intussusception safety risk
WHO CDC rotavirus vaccine intussusception risk updated 2023 2024 post-licensure surveillance
rotavirus vaccine RV5 RV1 efficacy severe gastroenteritis hospitalization
Rotavirus Vaccine Impact Assessment
Presentation · PPTX
What's in the deck (15 slides, ~12–15 min runtime)
| # | Slide | Content |
|---|---|---|
| 1 | Title | Navy/teal dark theme with orange accent for intussusception focus |
| 2 | Burden of Disease | Pre-vaccine era stats: 55,000–70,000 US hospitalizations/yr, ~215,000 global deaths, $1B cost |
| 3 | Vaccine History Timeline | RotaShield → RV5 → RV1 → WHO endorsement → post-licensure signal |
| 4 | Landmark RCT Design | Side-by-side comparison: Vesikari 2006 (n=68,038) vs. Ruiz-Palacios 2006 (n=63,225) |
| 5 | RotaTeq Efficacy | 74% any-grade, 98% severe, 96% hospitalizations |
| 6 | Rotarix Efficacy | 85% severe RVGE, 85% hospitalization reduction |
| 7 | Meta-Analysis Table | Sun et al., JAMA Pediatrics 2021 (PMID 33970192) — 20 RCTs + 38 case-controls |
| 8 | Real-World Effectiveness | ~90% decline US hospitalizations; herd immunity; 15-year Mexico data |
| 9 | What is Intussusception? | Dark slide — definition, peak age, classic triad, diagnosis, treatment |
| 10 | RotaShield Lesson | Why 1:10,000 caused withdrawal; pharmacovigilance lesson |
| 11 | Post-Licensure IS Data | VSD data: <1:65,287 (RV5); 5.3:100,000 (RV1); Australia 6:100,000 |
| 12 | Risk-Benefit Analysis | Side-by-side: 40,000+ hospitalizations prevented vs. 1–6 IS cases per 100,000 |
| 13 | Schedule & Contraindications | ACIP table; absolute CI: prior IS + SCID; special populations |
| 14 | Clinical Implications | 5 take-home messages for the resident |
| 15 | Summary & References | 10 key citations including all landmark RCTs and CDC guidelines |
Create PDF
Rotavirus Vaccine Impact Assessment
PDF Document · PDF
- PDF - for sharing/printing
- - for editing in PowerPoint
Rotavirus Vaccine Impact Assessment
Presentation · PPTX
Paper presentation on Impect assessment of rota virus vaccine on acute gastroenteritis and it's safety with focus on intussuception for pedia resident
- - Editable PowerPoint (15 slides)
Rotavirus Vaccine Impact Assessment
Presentation · PPTX
- - PDF version for sharing/printing
Rotavirus Vaccine Impact Assessment
PDF Document · PDF
- Title slide
- Burden of rotavirus disease (pre-vaccine era)
- Vaccine history timeline (RotaShield → RV5 → RV1)
- Landmark RCT design comparison (Vesikari 2006 vs. Ruiz-Palacios 2006)
- RotaTeq efficacy results (74–98%)
- Rotarix efficacy results (85%)
- Meta-analysis table (Sun et al., JAMA Pediatrics 2021)
- Post-licensure real-world effectiveness
- What is intussusception? (clinical review)
- RotaShield historical lesson
- Post-licensure IS data (VSD, Australia, global)
- Risk-benefit analysis (visual comparison)
- Vaccination schedule + contraindications (ACIP/AAP)
- Clinical implications for the pediatric resident
- Summary + 10 key references
Nothing in ppt and PDF
Rotavirus Vaccine Impact Assessment
Presentation · PPTX
Rotavirus Vaccine Impact Assessment
PDF Document · PDF